1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 13,600 | 15,200 | 25.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Transcript: Ascentage Pharma Group H1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| Do | Ascentage 1H 2026 slides: 29% revenue growth, 9 trials advance | 2 | Investing.com | ||
| Do | Ascentage Pharma Group International GAAP EPS of -$0.32 beats by $0.23, revenue of $44.5M misses by $7.73M | 2 | Seeking Alpha | ||
| Do | ASCENTAGE 1H26 Loss Widens to RMB817 million; No Interim Dividend | 1 | AASTOCKS | ||
| Do | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates | 228 | GlobeNewswire (Europe) | Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments... ► Artikel lesen | |
| Do | ASCENTAGE (06855): ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 2 | HKEx | ||
| 13.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie jetzt für 0€ handeln | |||||
| 05.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 | 1 | GlobeNewswire (USA) | ||
| 05.08. | ASCENTAGE (06855): NOTICE OF BOARD MEETING | 2 | HKEx | ||
| 03.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer | 137 | GlobeNewswire (Europe) | ROCKVILLE, Md., Aug. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery... ► Artikel lesen | |
| 03.08. | ASCENTAGE (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA APPOINTS DR. FAICAL MIYARA AS CHIEF BUSINESS OFFICER AND JIM ZIEGLER AS CHIEF COMMERCIAL ... | 2 | HKEx | ||
| 27.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.07. | Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know | 1 | Zacks | ||
| 27.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 | 1 | GlobeNewswire (USA) | ||
| 13.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.07. | ASCENTAGE (06855): UPDATE ON THE FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER THE POST ... | 1 | HKEx | ||
| 09.07. | How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23% | 1 | Zacks | ||
| 30.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.06. | ASCENTAGE (06855): FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER THE POST IPO SHARE OPTION ... | 1 | HKEx |
1 2 3 4 Weiter >>
79 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARIS LIFE SCIENCES | 24,000 | +6,19 % | Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance | Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole... ► Artikel lesen | |
| AKTIS ONCOLOGY | 26,720 | 0,00 % | Wedbush initiates Aktis Oncology stock with outperform rating | ||
| PARABILIS MEDICINES | 39,230 | +2,08 % | Parabilis Medicines, Inc. - 8-K, Current Report | ||
| APIMEDS PHARMACEUTICALS US | 4,720 | +2,39 % | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 13,360 | 0,00 % | Summit Therapeutics: Aktie legt nach Hochstufung durch Bernstein zu | ||
| APOGEE THERAPEUTICS | 134,85 | +0,04 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| QIAGEN | 36,710 | +0,84 % | Qiagen: Jonathan Pratt übernimmt den Vorstandsvorsitz | Qiagen bekommt zum 1. September 2026 einen neuen Vorstandschef. Jonathan M. Pratt übernimmt den Posten von Thierry Bernard, der als CEO und Geschäftsführer zurücktritt und den Übergang noch bis zum... ► Artikel lesen | |
| MODERNA | 135,86 | +14,07 % | Moderna Aktie explodiert: Krebsimpfstoff besteht entscheidende Studie | Die Moderna Aktie schießt am Mittwoch im US-vorbörslichen Handel um rund 85 Prozent nach oben, während die Merck Aktie etwa 7 Prozent gewinnt. Auslöser sind positive Phase-3-Daten für die gemeinsam... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,770 | +1,06 % | H.C. Wainwright hebt Kursziel für Tango Therapeutics auf 68 US-Dollar an | ||
| IMMUNOME | 29,385 | +4,91 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| IMMIX BIOPHARMA | 14,470 | 0,00 % | Kehoe Law Firm, P.C.: Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims | Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma")... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 37,430 | 0,00 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 126,71 | +4,68 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,555 | +1,57 % | Recursion, Novavax and Crispr Stocks Trending in Pre-Market-Here's Why | ||
| VERA THERAPEUTICS | 35,280 | 0,00 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen |
Das Unternehmen ASCENTAGE PHARMA GROUP INTERNATIONAL ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -8,00 % bei einem Aktienkurs von 13,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL ADR finden Sie auf Wallstreet Online.